The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
The chemistry will be single-molecule, based on hybridization, and will not require amplification, enzymes, or library prep, the firm said.
Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.
Executives from the sequencing tech firms provided attendees with an update on recently launched products and platforms, and future technology developments.
Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.
The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.
By a GenomeWeb staff reporter
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.